ALXO Q4 2025 Earnings Call Summary

ALX Oncology Holdings Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Cash Position: ALX ended Q4 2025 with cash, cash equivalents, and investments totaling $48.3 million. Following a recent equity financing, net proceeds amounted to $140.4 million, providing sufficient funding to support operations through 2028.
Net Loss: The GAAP net loss for Q4 2025 was $22.8 million ($0.42 per share), a decrease from a net loss of $29.2 million ($0.55 per share) in Q4 2024. This reduction is attributed to lower stock compensation, personnel costs, and preclinical expenses.

2. Strategic Updates and Business Highlights

Leadership: Dr. Barbara Klencke has been appointed as the permanent Chief Medical Officer, having previously served in an interim capacity.
Clinical Progress:
- Evorpocept (EVO): Over 750 patients treated, with promising data supporting its efficacy in HER2-positive gastric and breast cancers. The company aims to advance EVO to pivotal studies by the end of 2026.
- ALX 2004: The novel EGFR-targeted antibody-drug conjugate is progressing through dose escalation, with safety data expected in the second half of 2026.
Partnerships: Ongoing collaboration with Sanofi is highlighted, with expectations of significant data readouts from both clinical programs in the next 12-18 months.

3. Forward Guidance and Outlook

Milestones: Key upcoming milestones include:
- Full biomarker analysis from the phase 1/2 trial of EVO in HER2-positive breast cancer at the ESMO Breast Conference in May 2026.
- Safety data from the ALX 2004 trial anticipated in late 2026.
- Top-line data from the ongoing phase 2 ASPEN-9 breast cancer trial expected in mid-2027.
Enrollment Strategy: The ASPEN-9 trial is being expanded from 80 to 120 patients to ensure robust data on CD47 expression and response rates.

4. Bad News, Challenges, or Points of Concern

Clinical Risks: The company faces inherent risks associated with clinical trials, including potential delays or unfavorable results that could impact regulatory strategy and market entry.
Market Competition: The evolving treatment landscape for HER2-positive cancers presents challenges, particularly as new therapies are introduced, potentially affecting the positioning of ALX's products.
Biomarker Variability: There are concerns regarding the variability in CD47 expression across different tumor types, which may complicate patient selection and efficacy predictions.

5. Notable Q&A Insights

EVO Trial Design: The decision to increase the ASPEN-9 trial size was driven by the need for robust data on CD47 expression, which is crucial for regulatory discussions.
Investigator Feedback: There is strong enthusiasm among investigators regarding the biomarker-driven approach, with expectations that it will enhance treatment outcomes for targeted patient populations.
Therapeutic Window: Questions regarding ALX 2004's dosing strategy indicated confidence in a wider therapeutic window based on preclinical data, with ongoing monitoring for potential toxicities such as interstitial lung disease and skin toxicity.

Overall, ALX Oncology is positioned for significant clinical milestones in the coming years, with a strong financial foundation and promising data supporting its lead programs. However, the company must navigate clinical and competitive challenges as it advances its therapies.

ALXO — ALX Oncology Holdings Inc.